About us Pricing ContactSubscribe

Y

Yasmine Wasfi

Janssen (United States)

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Journal of the American Academy of Dermatology2017841 citations

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Journal of the American Academy of Dermatology2017718 citations

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

British Journal of Dermatology2013406 citations

Yasmine Wasfi · Scinovex